Nurix Therapeutics Files 8-K on Shareholder Votes & Exhibits

Ticker: NRIX · Form: 8-K · Filed: May 19, 2025 · CIK: 1549595

Sentiment: neutral

Topics: corporate-governance, filing, financials

Related Tickers: NRIX

TL;DR

Nurix filed an 8-K for shareholder votes and financials - check for details.

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filing does not detail specific votes or financial figures but serves as a notification of these events.

Why It Matters

This filing indicates important corporate actions, such as shareholder votes and the submission of financial documents, which are crucial for investors to monitor company governance and financial health.

Risk Assessment

Risk Level: low — This is a routine filing that primarily serves as a notification of corporate events without disclosing new material financial information or significant strategic changes.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What financial statements and exhibits are being filed?

The filing states that Financial Statements and Exhibits are being filed, but the specific content of these documents is not detailed in the provided text.

What is the exact date of the earliest event reported?

The earliest event reported is May 19, 2025.

What is Nurix Therapeutics, Inc.'s principal executive office address?

Nurix Therapeutics, Inc.'s principal executive office is located at 1700 Owens Street, Suite 205, San Francisco, California.

What is the company's IRS Employer Identification Number?

The company's IRS Employer Identification Number is 27-0838048.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Nurix Therapeutics, Inc. (NRIX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing